仙琚制药: 仙琚制药第八届监事会第十次会议决议公告

Core Viewpoint - The company has decided to dissolve a joint venture based on its own development and management considerations, ensuring compliance with relevant laws and regulations [1][2]. Group 1 - The eighth supervisory board meeting was held on August 10, 2025, with all seven supervisors participating, and the decision to dissolve the joint venture was passed with six votes in favor [1]. - The decision to dissolve the joint venture was made without harming the interests of the company and all shareholders, particularly minority shareholders [2]. - The related director recused themselves from the voting process to ensure compliance with legal and procedural requirements [2].